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Leukemia results from genetic defects that lead 
to enhanced proliferation and survival of bone 
marrow–derived cells, disrupting homeostasis 
in the hematopoietic compartment. Chronic 
myelogenous leukemia (CML) is a malignant 
myeloproliferative disease (MPD) that com-
prises 15–20% of hematopoietic cancers in hu-
mans (1). It is typifi  ed by an initial chronic 
stage, during which patients experience spleno-
megaly secondary to myeloid cell expansion. 
This relatively benign phase of the disease often 
progresses to a fatal blast crisis within 3–5 yr 
of diagnosis (1). The Philadelphia chromo-
some, the consequence of a t(9;22) (q34;q11) 
translocation, is a hallmark of the majority of 
human CML (2) and results in a fusion be-
tween  bcr and the tyrosine kinase abl. The 
product of the Bcr-Abl fusion is altered in its 
cellular distribution and exhibits constitutive 
tyrosine kinase activity compared with c-Abl. 
Consequently, hyperphosphorylation of key 
Bcr-Abl substrates promotes leukemogenesis 
in myeloid cells (2).
Exciting advances in molecular medicine 
have yielded imatinib mesylate/STI571/
Gleevec, an inhibitor of Abl activity, which 
has proved to be eff  ective in many patients 
with CML (3). Unfortunately, a subset of pa-
tients affl   icted with myeloid leukemias initially 
  exhibit imatinib resistance, whereas others be-
come refractory to treatment owing to devel-
opment of drug resistance caused by subsequent 
mutations in abl (4–7). Moreover, evolution 
of CML to blast crisis is characterized by the 
development of a degree of resistance to treat-
ment that is notoriously diffi   cult to overcome 
(1, 6, 8). The survival of STI571-resistant leu-
kemic cells can be mediated by compensatory 
activation of the Ras/mitogen-activated pro-
tein kinase and phosphatidylinositol 3–kinase 
(PI3-K)/Akt signaling cascades (9, 10). Thus, 
targeting these pathways may not only treat 
leukemic disease but can also circumvent the 
development of STI571 resistance.
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Though Abl inhibitors are often successful therapies for the initial stages of chronic my-
elogenous leukemia (CML), refractory cases highlight the need for novel molecular insights. 
We demonstrate that mice defi  cient in the enzyme 12/15-lipoxygenase (12/15-LO) develop 
a myeloproliferative disorder (MPD) that progresses to transplantable leukemia. Although 
not associated with dysregulation of Abl, cells isolated from chronic stage 12/15-LO–defi  cient 
(Alox15) mice exhibit increased activation of the phosphatidylinositol 3–kinase (PI3-K) 
pathway, as indicated by enhanced phosphorylation of Akt. Furthermore, the transcription 
factor interferon consensus sequence binding protein (ICSBP) is hyperphosphorylated and 
displays decreased nuclear accumulation, translating into increased levels of expression of 
the oncoprotein Bcl-2. The ICSBP defect, exaggerated levels of Bcl-2, and prolonged leuke-
mic cell survival associated with chronic stage Alox15 MPD are all reversible upon treat-
ment with a PI3-K inhibitor. Remarkably, the evolution of Alox15 MPD to leukemia is 
associated with additional regulation of ICSBP on an RNA level, highlighting the potential 
usefulness of the Alox15 model for understanding the transition of CML to crisis. Finally, 
12/15-LO expression suppresses the growth of a human CML–derived cell line. These data 
identify 12/15-LO as an important suppressor of MPD via its role as a critical upstream 
effector in the regulation of PI3-K–dependent ICSBP phosphorylation.
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Though several elegant mouse models have been devel-
oped to study myeloid leukemias (11–14), many of these 
  develop fulminant blast crisis within weeks of induction, 
  limiting their usefulness for investigating the chronic phase of 
CML and the critical transition to blast crisis phase (2). One 
of the few exceptions is the MPD observed in mice defi  cient 
in interferon consensus sequence binding protein/interferon 
regulatory factor 8 (ICSBP/IRF-8), which is characterized 
by more gradual and less frequent transitions to leukemic 
blast crisis (15). Importantly, the loss of ICSBP expression in 
patients with CML correlates with disease progression (16), 
whereas forced expression induces apoptosis in cell lines es-
tablished from patients with Bcr-Abl+ CML (17, 18), even in 
cells which are STI571 resistant (19). However, despite the 
importance of ICSBP in human CML, none of the regula-
tory pathways upstream of ICSBP have been defi  ned in 
the context of leukemia. In this study, we demonstrate that 
12/15-lipoxygenase (12/15-LO) regulates ICSBP, and thereby 
MPD, in a PI3-K–dependent manner.
Lipoxygenases are enzymes that incorporate oxygen into 
unsaturated lipids and are named according to the position 
of the carbon double bonds they oxidize (20). These reac-
tions yield short-lived peroxidized products, such as 12(S)-
hydroperoxyeicosatetraenoic acid (12(S)-HpETE) and 13(S)-
hydroperoxyoctadecadienoic acid, which reduce or are 
  actively converted to several diff  erent products, including 
12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), 13(S)-
hydroxyoctadecadienoic acid (13(S)-HODE), lipoxins, and 
hepoxilins. Importantly, the levels of the lipoxygenase prod-
uct derivative 12(S)-HETE are reduced in patients with 
CML compared with normal controls (21), suggesting a role 
for lipoxygenase activity in the suppression of this disease. 
Consistent with this hypothesis, expression of platelet 
12-  lipoxygenase (encoded by Alox12) inversely   correlates 
Figure 1.  Decreased survival and marked splenomegaly in 12/15-
LO–defi  cient mice. (a) Kaplan-Meier plot of 102 wild-type (B6) and 113 
Alox15 mice representing a nearly 1:1 ratio of males/females. (b) Repre-
sentative spleens of 10–12-wk-old wild-type, asymptomatic (Asx), and 
moribund Alox15 mice. (c) Mean wet weights ± SD of the spleens shown 
in b (n = 18 for B6 and Asx Alox15 mice; n = 9 for moribund Alox15 mice). 
*, P < 0.0001.
Figure 2.  Disrupted architecture and increased myeloid cells in the 
spleens of 12/15-LO–defi  cient mice. (a) H&E staining of 8-μm frozen 
sections of spleens from wild-type (n ≥ 10), Asx Alox15 (n ≥ 10), and 
  moribund Alox15 mice (n = 7). WP, white pulp; RP, red pulp. Bar, 50 μm. 
Fluorescence-activated fl  ow cytometric analysis of (b) B cell populations, 
(c) T cell populations, and (d) myeloid populations in isolated splenocytes of 
representative samples gated on live cells. Percentages for each quadrant 
are indicated. Mac-1/GR-1 double-positive cells increased from a range of 
1.8–8.2% in wild-type (n = 11) to 15–24% and 35–70% in the spleens of 
Alox15 mice in the chronic (n = 9) and crisis (n = 4) phases, respectively. 
(e) Differential counts of cytospin preparations of splenocytes from asymp-
tomatic (Asx) and moribund Alox15 mice versus wild-type controls.JEM VOL. 203, October 30, 2006  2531 
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with the severity of CML disease (22). Similarly,   leukocyte 
12/15-LO (encoded by Alox15) is located on a region of hu-
man chromosome 17 implicated in the suppression of  myeloid 
leukemogenesis (23). Despite these intriguing data, no direct 
evidence had yet supported a role for lipoxygenases in regu-
lating leukemogenesis. While conducting experiments with 
12/15-LO–defi  cient (Alox15) mice, we discovered that they 
develop an indolent MPD akin to human CML. We now 
provide the fi  rst description of Alox15 mice as a model for 
MPD and demonstrate that the pathology in these animals is 
related to 12/15-LO–mediated PI3-K–dependent regulation 
of ICSBP and its downstream target genes in vivo.
Figure 3.  Increased myeloid cells in the bone marrow, blood, and 
lymph node of 12/15-LO–defi  cient mice. (a, top) Representative 
(n = 6) wild-type (B6) and Alox15 bone marrow cells. Note the large mega-
karyocyte (black arrowhead) in the asymptomatic (Asx) Alox15 cells. Green 
arrowheads indicate myeloblasts. Note the presence of basophilic cytoplasm, 
prominent nucleoli, undefi  ned granules, and the absence of Auer rods (Auer 
rods would support a diagnosis of acute myeloid leukemia; reference 56). Bar, 
50 μm. (a, middle) Representative fl  ow cytometric analysis of Mac-1 and Gr-1 
expression in bone marrow. Percentages for each quadrant are indicated. 
Double-positive ranges: C57BL/6, 35.9–52.7% (n = 7); Asx Alox15, 43.8–
61.2% (n = 7); and moribund Alox15, 61.9–90.1% (n = 5). (a, bottom) Gr-1 
and CD34 expression in bone marrow. Percentages for each quadrant are 
indicated. Double-positive ranges: C57BL/6, 4.5–9.1% (n = 5); Asx Alox15, 
11.2–17.9 (n = 4); and moribund Alox15, 25.8–33.1% (n = 3). (b, top) 
C57BL/6 and Alox15 blood smears. Note the platelet anisocytosis and micro-
megakaryocytosis often found in CML. Black arrows point to examples of 
basophils, and green arrowheads indicate example blast cells. Bar, 50 μm. 
(b, bottom) Flow cytometric analysis of Gr-1 expression in blood leukocytes 
from 25-wk-old B6, Asx Alox15, and moribund Alox15 mice. Percentages of 
Gr-1+ cells are indicated. Gr-1+ ranges: B6, 42.5–51% (n = 5); Asx Alox15, 
62–79.2% (n = 5); and moribund Alox15, 68.2–90.% (n = 3). (c, top) H&E-
stained sections of wild-type and chronic Alox15 lymph node. Arrowheads 
point to pseudo-Gaucher–like cells. (c, bottom) Immunohistochemical stain-
ing for Gr-1+ cells in B6 and Alox15 lymph node. Bar, 50 μm.2532  12/15-LO SUPPRESSES MYELOPROLIFERATIVE DISEASE | Middleton et al.
RESULTS
12/15-LO–defi  cient mice develop a MPD
Though we observed no gross diff  erences in the tissue com-
position of Alox15 mice compared with wild-type controls at 
6–8 wk of age (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20061444/DC1), we noted a small but 
distinct increase in the death rate of homozygous knockout 
animals as they aged compared with wild-type controls (Fig. 
1 a). Furthermore, examination of outwardly healthy Alox15 
mice older than 8 wk revealed varying degrees of splenomegaly 
with 100% penetrance compared with wild-type controls 
(Fig. 1, b and c). Early morbidity and mortality was associated 
with increasingly severe splenomegaly (Fig. 1, b and c).
Analysis of splenic architecture revealed a remarkable de-
crease in the number of follicles and disrupted compartmen-
talization of the red and white pulp in the asymptomatic 
Alox15 compared with wild-type mice (Fig. 2 a). Strikingly, 
severe splenomegaly in moribund Alox15 mice was charac-
terized by complete loss of splenic compartmentalization 
(Fig. 2 a). Phenotypic analysis of wild-type and Alox15 sple-
nocytes by fl  ow cytometry revealed a selective increase in the 
Mac-1+/GR-1+ (myeloid) population (Fig. 2, b–d), whereas 
diff   erential counts of cytospin preparations of splenocytes 
from Alox15 mice versus wild-type controls demonstrated 
no expansion of other cell types (Fig. 2 e). Bone marrow was 
also aff  ected, where the numbers of myeloid cells and their 
CD34+/Gr-1lo progenitors (24), as well as megakaryocytes 
(25), were increased at the expense of erythropoiesis (Fig. 3 a 
and Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20061444/DC1). Moribund animals regularly dem-
onstrated more than 25% myeloblast cells in the bone marrow 
by morphology and CD34 expression (thus, these animals are 
herein referred to as being in blast crisis stage).
Asymptomatic Alox15 mice, whose spleens were at least 
twice the weight of wild-type controls, as well as all of those 
in the crisis stage, also displayed blood leukocytosis and baso-
philia, with myeloblasts apparent in the moribund mice (Fig. 
3 b). Furthermore, though the lymph nodes were not grossly 
enlarged, they exhibited progressive hypercellularity and 
morphological changes, with pseudo-Gaucher cells present 
(Fig. 3 c) (26). Immunohistochemistry revealed a marked in-
crease in the proportion of GR-1+ cells in lymph node in 
both asymptomatic and moribund compared with wild-type 
animals (Fig. 3 c). We also detected myeloid infi  ltrates in 
the skin of most moribund Alox15 mice that correlated with 
the development of dermatitis (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20061444/DC1), a poor 
prognostic sign in human CML (27). In contrast, other tissues 
(liver, kidney, lungs, and heart) displayed no evidence of 
  pathology (unpublished data).
Overall, the data up to this point indicate that Alox15 
mice develop a MPD. Considering the pathology described, 
including the percentage of myeloblasts in the bone marrow, 
we classifi  ed 10 wk and older asymptomatic Alox15 mice 
with less severe pathology as being in the chronic phase 
( 85% of the population) and the moribund mice ( 15% of 
the population) as being in crisis phase. Furthermore, the pa-
thology observed in these mice suggests that the most likely 
cause of death in the moribund mice was the severe anemia 
in these animals (Fig. S2).
12/15-LO activity suppresses proliferation and 
survival in mouse and human myeloid cells
We observed signifi   cantly increased proliferative capacity 
in splenic Alox15 myeloid cells based on cell cycle analysis 
(Fig. 4, a and b). In addition, the percentage of apoptotic cells 
was decreased in Alox15 compared with wild-type cells, 
Figure 4.  12/15-LO suppresses proliferation and survival in mouse 
and human cells. (a) Flow cytometric analysis of propidium iodide–
stained wild-type (B6) and chronic Alox15 (Chr) sorted Gr-1+ splenocytes. 
(b) Quantifi  cation of data shown in panel a. *, P = 0.01 compared with B6 
(n = 3). (c) The percentage of apoptotic cells in B6 and Alox15 myeloid 
cells from 10–20-wk-old B6 and Alox15 mice after 24-h culture was quan-
tifi  ed using propidium iodide staining. *, P = 0.002 compared with B6 
(n = 4). (d) Immunoblot of 12/15-LO in K562 cells transfected with a vector 
control or mouse 12/15-LO, as compared with sorted B6 splenic macro-
phages (Mac). An anti–human 12/15-LO antibody that cross reacts with 
mouse (not depicted) was used. Samples were normalized for protein con-
centration. (e) The number of viable K562 cells 24 h after transfection (Tx) 
with 12/15-LO or vector control (Ctl) in the presence of 10 μM PD146176 
(PD146) or DMSO vehicle control was quantifi  ed using trypan blue exclusion. 
*, P = 0.0268 compared with Ctl DMSO (n = 3); #, P = 0.0256 compared 
with 12/15-LO DMSO (n = 3). (f) Proliferation index after 24 h of trans-
fected K562 cells, as measured by the fold increase in viable cells treated 
with 10 μM PD146176 or DMSO vehicle control. *, P = 0.0149 compared 
with Ctl DMSO (n = 3); #, P = 0.005 compared with 12/15-LO DMSO 
vehicle. All error bars represent means ± SD.JEM VOL. 203, October 30, 2006  2533 
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  indicating enhanced survival of Alox15 cells (Fig. 4 c). We 
then investigated the relevance of 12/15-LO to human 
MPD. Consistent with the potential role of 12/15-LO in 
suppressing human disease, we found that human Bcr-Abl+ 
leukemia K562 cells (28), despite being derived from the my-
eloid lineage (which generally expresses 12/15-LO), do not 
express detectable levels of 12/15-LO protein (Fig. 4 d). 
However, forced expression resulted in levels of 12/15-LO 
similar to those found in mouse macrophages (Fig. 4 d) and 
led to a decrease in cell survival and proliferation that could 
be overcome by treatment with the 12/15-LO inhibitor 
PD146176 (Fig. 4, e and f). Thus, 12/15-LO can suppress 
human as well as mouse MPD.
The MPD in 12/15-LO–defi  cient mice is cell autonomous
To assess whether the MPD in Alox15 tissues fi  t the classifi  -
cation of a leukemia (29), we tested whether the Alox15 phe-
notype was cell autonomous by transplanting Alox15 cells 
into syngeneic, nonirradiated wild-type mice. The splenic 
enlargement and disrupted compartmentalization, as well as 
the myeloid cell expansion, we observed in Alox15 mice was 
uniformly recapitulated in wild-type recipients transplanted 
with crisis stage splenocytes or bone marrow cells as early as 
4 wk after transfer (Fig. 5, a–c). Though transplant of cells 
from 10–12-wk-old chronic stage Alox15 mice did not result 
in overt pathology in wild-type recipients, the cells from 
these mice were transplantable to mice with severe combined 
immunodefi  ciency in 4 out of 6 cases (Fig. 5 c). Moreover, 
though it was not possible to assess clonality of the transferred 
cells, persistence of Alox15 cells in the donor mice was con-
fi  rmed by PCR for the neomycin cassette introduced by the 
Alox15 targeting vector (Fig. 5 d). We conclude from these 
data that Alox15 mice develop a MPD that transitions to a 
transplantable leukemia in a subset of animals over time.
Role of 12/15-LO lipid mediators in suppressing 
leukemogenesis
To address the potential role of lipid mediators in 12/15-
LO’s impact on myeloid proliferation, we measured the lipid 
products released ex vivo during whole organ culture of 
Alox15 versus wild-type spleens. We found that Alox15 mice 
produced comparable amounts of 15(S)-HETE, lipoxin A4, 
and 5(S)-HETE (a 5-lipoxygenase product) but reduced lev-
els of 12(S)-HETE and 13(S)-HODE compared with wild-
type controls (Fig. 6, a–e), indicating that 12(S)-HETE and 
13(S)-HODE or their intermediates are the most likely lipid 
products to be involved in 12/15-LO–mediated suppression 
of leukemogenesis. This is consistent with the observation 
that a stable analogue of the 12(S)-HpETE derivative, hep-
oxilin A4, can suppress the growth of K562 cells in in vivo 
models (30). Indeed, we found that 12(S)-HpETE displayed 
a modest ability to suppress viability in Alox15 and K562 cells 
(Fig. 6 f). The eff   ects of 12(S)-HpETE on viability may, 
however, be minimized in these studies because of its lability 
and potential to act in synergy with other 12/15-LO pro-
ducts in vivo.
Alox15 MPD is Abl independent
Others have demonstrated that Abl hyperactivity in myeloid 
cells, associated with v-Abl or Bcr-Abl, can induce MPD in 
mice (12, 31). These studies compelled us to explore whether 
12/15-LO expression may prevent MPD by suppressing en-
dogenous Abl activity. To do this, we used concentrations of 
the Abl inhibitor STI571 suffi   cient to inhibit endogenous 
Abl activity. We found that, in contrast to the K562 cells 
(Fig. 7 a), Alox15 splenocytes did not undergo cell cycle ar-
rest or apoptosis upon treatment with the Abl inhibitor 
STI571/imatinib (Fig. 7 b). We also used the endogenous 
Abl substrate Crk (32), rather than the pathologic Bcr-Abl 
Figure 5.  The MPD in 12/15-LO–defi  cient mice is cell autonomous. 
(a) Increased splenic weight, (b) representative H&E-stained cryostat 
  sections of spleens, and (c) cytospins of splenocytes from 8–10-wk-old 
wild-type mice injected via the tail vein with 0.5 × 106 (Alox15 crisis) or 
107 (Alox15 chronic and C57BL/6) splenocytes or 2 × 106 bone marrow 
cells, monitored every other day, and killed at 6 or 10 wk after transfer. 
Bar, 50 μm. (d) 2% agarose electrophoresis of PCR products for the neo-
mycin cassette performed on DNA extracted from spleens taken from 
mice transplanted with B6 (B6 Trx) or Alox15 (ATrx) cells versus Alox15 tail 
DNA positive control. (e) Table summarizing transfer experiments per-
formed as described in panel a. Splenic distortion was assessed blindly. 
All error bars represent means ± SD.2534  12/15-LO SUPPRESSES MYELOPROLIFERATIVE DISEASE | Middleton et al.
substrate CrkL, to assess whether endogenous Abl activity 
was increased, as endogenous Abl may not be capable of 
phosphorylating CrkL to the degree that Bcr-Abl can (33). 
Nonetheless, we detected levels of phosphorylation of the 
major Abl substrate Crk that were comparable to the wild 
type (Fig. 7, c and d). Thus, at least in the ex vivo environ-
ment, the Alox15 MPD is independent of Abl activity.
Dysregulation of ICSBP and enhanced Bcl-2 expression 
in myeloid cells isolated from Alox15 mice
Given the importance of ICSBP in MPD (15), as well as 
our previous data demonstrating the ability of 12/15-LO to 
regulate ICSBP in other contexts (34), we hypothesized 
that 12/15-LO aff  ects hematopoiesis by regulating ICSBP. 
Consistent with this hypothesis, we found that ICSBP nu-
clear levels were reduced in splenocytes from Alox15 mice 
and were barely detectable in splenocytes from mice that 
had progressed to blast crisis (Fig. 8 a). Real-time PCR for 
ICSBP revealed that its transcript levels in chronic stage 
Alox15 mice were comparable to the wild type, suggesting 
posttranslational regulation of ICSBP in this phase of the 
disease. On the other hand, expression of the ICSBP gene 
was nearly ablated in splenocytes isolated from mice in cri-
sis (Fig. 8 b). This suggests that ICSBP is diff  erentially reg-
ulated between the chronic and crisis stages of Alox15 MPD 
and that ICSBP expression inversely correlates with disease 
progression in Alox15 mice, as in the case of CML (16). 
As the decreased ICSBP expression in blast crisis mice was 
on an RNA level and, thus, caused by the gain of genetic mu-
tations or transcriptional dysregulation that may complicate 
the interpretation of our experiments, we have focused our 
eff  orts in this study on elucidating the posttranslational mech-
anisms by which 12/15-LO regulates ICSBP in chronic stage 
Alox15 cells.
To investigate chronic stage Alox15 MPD, it was impor-
tant to confi  rm that the decrease in nuclear levels of ICSBP 
in unfractionated chronic stage Alox15 splenocytes was a re-
fl  ection of ICSBP dysregulation in chronic stage Alox15 my-
eloid cells. To do this, we examined the levels of ICSBP in 
enriched populations. Consistent with the RNA levels we 
observed in unfractionated spleens, chronic stage myeloid 
cells expressed similar ICSBP transcripts to wild-type controls 
(Fig. 8 c). However, we detected considerably lower nuclear 
levels of ICSBP protein in the Mac-1+/GR-1+ splenocyte 
populations isolated from Alox15 mice compared with those 
isolated from wild-type mice (Fig. 8 d). In contrast, the cyto-
plasmic levels of ICSBP in Alox15 myeloid cells were com-
parable to the wild type, indicating a nuclear accumulation 
defect (Fig. 8 d). The selectively decreased nuclear levels of 
Figure 6.  12/15-LO–defi  cient MPD may be due in part to the loss 
of lipid mediators. Mass spectrometric or (in the case of lipoxin A4) ELISA 
analysis of the release per mg of tissue of (a) 5(S)-HETE, (b) lipoxin A4, 
(c) 12(S)-HETE, (d) 13(S)-HODE, and (e) 15(S)-HETE in PMA and ionomycin-
stimulated unperfused spleens (n = 4). *, P = 0.0058; #, P = 0.0006. 
Shaded and open bars represent C57BL/6 and chronic Alox15 mice, 
  respectively. (f) 24-h viability in Alox15 chronic(Chr) or K562 cells treated 
overnight with 60 μM 12(S)-HpETE, a direct 12/15-LO product. *, P = 0.013 
(n = 3); #, P = 0.003 (n = 3). All error bars represent means ± SD.
Figure 7.  Alox15 MPD is Abl independent. Quantifi  cation of (a)   cycling 
and (b) apoptotic K562 cells treated for the indicated times with 16 μM 
STI571 or DMSO vehicle control. *, P = 0.036 compared with DMSO control 
(n = 3); #, P = 0.042 compared with DMSO control (n = 3). Quantifi  cation 
of (c) cycling and (d) apoptotic cells in C57BL/6 wild-type or chronic Alox15 
(Chr) splenocytes treated for the indicated times with 16 μM STI571 or DMSO 
vehicle control (n = 3). (e) Crk immunoprecipitation (IP) and immuno  blot for 
phosphotyrosine (P-tyr) or Crk loading control of cytoplasmic lysates pre-
pared from B6 and chronic Alox15 splenocytes (n = 4). (f) Quantifi  cation of 
the data shown in e. All error bars represent means ± SD.JEM VOL. 203, October 30, 2006  2535 
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ICSBP in the myeloid population, compared with the Mac-
1−/GR-1− population, reinforce the conclusion that the 
  aberrant cells in Alox15 mice are contained within the mye-
loid compartment, which is consistent with the selective 
  expression of 12/15-LO in the myeloid lineage (Fig. 8 d).
To ascertain whether the regulation of ICSBP nuclear 
accumulation by 12/15-LO corresponds with changes in the 
expression of ICSBP target genes, we measured levels of 
Bcl-2, an oncoprotein known to be suppressed by ICSBP 
(19, 35), in myeloid cells. We observed a dramatic up-
  regulation of Bcl-2 in the Alox15 myeloid population (Fig. 
8 d) that correlated inversely with the nuclear accumulation 
of ICSBP.
PI3-K regulates Alox15 myeloproliferative cell survival and 
ICSBP phosphorylation and nuclear accumulation
Given the impact of tyrosine phosphorylation events on the 
ability of ICSBP to serve as a repressor of gene expression 
(36), we postulated that 12/15-LO regulates the nuclear ac-
cumulation and function of this transcription factor by infl  u-
encing its phosphorylation status. Indeed, immunoprecipitation 
studies revealed an increase in tyrosine phosphorylation of 
ICSBP in Alox15 spleen (Fig. 9 a), indicating an important 
role for 12/15-LO in suppressing ICSBP phosphorylation.
Because the PI3-K pathway can promote Abl-independent 
CML, and in view of the capacity of 12/15- LO to regulate 
PI3-K in other settings (37), we explored the possibility that 
the dysregulation of ICSBP in Alox15 cells is PI3-K dependent. 
Indeed, we found increased levels of phosphorylation of the 
PI3-K pathway product Akt in bone marrow myeloid cells 
from Alox15 mice (Fig. 9 b). Conversely, treatment with the 
PI3-K inhibitor Ly294002 suppressed ICSBP phosphorylation 
and restored nuclear levels of ICSBP to that of the wild type 
(Fig. 9, c–f). This led to a correction in Bcl-2 transcript levels 
in Alox15 myeloid cells and induction of apoptosis in these 
cells within 24 h (Fig. 9, g and h). These data establish a mech-
anistic link between PI3-K and ICSBP and indicate that 
12/15-LO regulates myeloid leukemogenesis by aff  ecting the 
PI3-K signaling pathway.
D  I  S  C  U  S  S  I  O  N 
This study establishes 12/15-LO as a critical and somewhat 
unexpected regulator in the suppression of MPD. We also 
place 12/15-LO in mechanistic context by demonstrating its 
impact on the phosphorylation and nuclear localization of 
ICSBP, as well as that the ICSBP dysregulation in and sur-
vival of aberrant Alox15 cells is PI3-K dependent.
We found that Alox15 mice older than 10 wk develop 
MPD with 100% penetrance. In considering a novel mouse 
model for leukemic disease, it is important to evaluate the pre-
leukemic state, pathology in knockouts as well as controls, and 
to assess the transferability of the leukemic syndrome (29), all 
of which we have done. However, one should, if possible, also 
investigate whether the disease is clonal in nature using antigen 
receptor rearrangement or retroviral insertion sites. Unfortu-
nately, given the strictly myeloid nature of the syndrome in 
our mice and the fact that these animals are free of retroviral 
insertions, none of the conventional methods were available to 
us to establish clonality (29). Therefore, though the persistence 
of transplanted Alox15 cells 10 wk after transfer to wild-type 
recipients strongly suggests the clonal derivation of these cells, 
we have opted to make the more conservative conclusion that 
Alox15 mice develop a MPD that may become leukemic. 
Further studies, perhaps using a nontransforming retrovirus, 
will be required to completely elucidate this issue.
Figure 8.  ICSBP defect and enhanced Bcl-2 expression in cells 
from Alox15 mice. (a) Immunoblot of nuclear extracts prepared from 
wild-type (B6), chronic Alox15 (Chr), and crisis Alox15 (Cri) splenocytes 
using antibodies specifi  c for ICSBP and normalized to total protein, as 
confi  rmed by coomassie stain (loading). (b) Real-time PCR analysis of 
ICSBP mRNA expression levels in wild-type, chronic Alox15, and crisis 
Alox15 splenocytes. *, P = 0.0115 and 0.0284 compared with B6 and Chr, 
respectively. (c) Real-time PCR of sorted myeloid splenocytes isolated 
from C57BL/6 and chronic stage Alox15 mice. (d) Representative immuno-
blot of nuclear (above line) and cytoplasmic (below line) extracts prepared 
from sorted wild-type and Alox15 splenocytes for ICSBP, 12/15-LO, Bcl-2, 
and the loading controls histone 2b and total actin. The results are repre-
sentative of three experiments. All error bars represent means ± SD.2536  12/15-LO SUPPRESSES MYELOPROLIFERATIVE DISEASE | Middleton et al.
Given the indolent nature of the MPD that occurs in 
Alox15 mice, these animals provide a relatively unique op-
portunity to study the mechanisms underlying the chronic 
stage of MPD and its transition to blast crisis. In fact, as with 
humans with CML, we have found in this study that ICSBP 
is regulated diff  erently in chronic and crisis stage cells, which 
appears to aff  ect downstream targets of this transcription factor. 
In the future, it will be important to distinguish whether 
the switch to crisis is a result of transcriptional regulation of 
ICSBP by 12/15-LO or is caused by mutations in this gene. 
Indeed, it is possible that the occurrence of genetic aberran-
cies in ICSBP are a prerequisite of blastic transformation 
given the near uniform reduction in ICSBP transcripts in 
  patients with crisis stage CML (16). Thus, further studies to 
defi  ne mechanisms of blastic transformation in indolent mod-
els of CML such as Alox15 mice are critical to developing 
new therapies. Moreover, as we have shown that 12/15-LO 
is expressed selectively in the myeloid lineage among hema-
topoietic cells, this pathway may present a selective target for 
treating MPD.
Curiously, though Alox15 mice were generated nearly a 
decade ago, the MPD we describe in this manuscript was not 
previously reported. There are several possible explanations 
for this. One possibility is that the syndrome in Alox15 may 
have become more pronounced on the pure C57BL/6 ge-
netic background described in this study, as opposed to the 
F = 7 animals previously studied. Additionally, the majority 
of Alox15 mice manifests a degree of splenomegaly that 
might not be obvious to investigators handling the mice for 
other purposes and, therefore, who are not focused on the 
integrity of lymphoid organs. This is less likely in the case of 
the more dramatic splenomegaly observed in mice in blast 
crisis, but the incidence of these mice is relatively low 
( 15%). Importantly, scientists at the Jackson Laboratory, 
the vendor of Alox15 mice (see Materials and methods), have 
recently examined Alox15 mice versus wild-type controls 
and have observed a similar phenotype of splenomegaly and 
fl  ow cytometric abnormalities, confi  rming our fi  ndings in an 
independent facility (Nicholson, A., personal communication). 
The history of Alox15 mice mirrors the plight of   human 
CML patients who, because of their initially mild symp-
toms, are often considered healthy for some time before 
  being diagnosed.
We demonstrated that 12/15-LO–mediated suppression 
of leukemic cell growth is dependent on its enzymatic activ-
ity, and our ex vivo data suggest that 12/15-LO is responsible 
for producing several lipid mediators in vivo, including 12(S)-
HETE. Interestingly, others have shown decreased levels of 
12(S)-HETE in the bone marrow of humans with CML (21). 
This eff  ect may be caused in part by reduced levels of plate-
let 12-lipoxygenase RNA levels in CML patients (22). The 
common products between leukocyte and platelet 12-
  lipoxygenases likely explain the fact that these enzymes are 
often jointly implicated in disease pathology, as exemplifi  ed 
in the case of osteoporosis (38, 39). Another reason for the 
overlapping functions between these two enzymes may be 
transcellular oxidation products formed between platelets and 
leukocytes, such as lipoxins and their intermediates (40–42). 
Alternatively, other consequences of lipoxygenase activity, 
such as direct membrane oxidation and reactive oxygen spe-
cies, may be involved (20).
Consistent with the mechanistic links between them, the 
ICSBP and 12/15-LO–defi  cient mouse models for human 
MPD share several characteristics. Indeed, the decreased sur-
vival in ICSBP heterozygotes (9%) (15) is similar to what we 
observed in 12/15-LO–null mice, which would be expected 
Figure 9.  PI3-K regulates Alox15 myeloproliferative cell survival 
and ICSBP phosphorylation and nuclear accumulation. (a) Immunoblot 
of ICSBP immunoprecipitated from wild-type (B6) and chronic Alox15 (Chr) 
splenocyte total lysates. (b) Constitutive levels of phosphorylated Akt in 
bone marrow myeloid cells cultured for 5 d in GM-CSF. (c) Splenocytes were 
cultured for 6 h in 16 μM Ly296002 or DMSO vehicle control, and samples 
were prepared and analyzed as in panel a. (d) Quantifi  cation of the data 
shown in c (n = 3). *, P = 0.0012 compared with B6 DMSO; #, P = 0.0081 
compared with Chr DMSO. (e) Nuclear extracts of cells treated as in c. 
(f) Quantifi  cation of the data shown in e (n = 3). *, P = 0.0052 compared 
with B6 DMSO; #, P = 0.0155 compared with Chr DMSO. (g) Real-time PCR 
of Bcl-2 transcripts in sorted myeloid splenocytes from C57BL/6 and Alox15 
cells. *, P = 0.001; #, P = 0.02. (h) Quantifi  cation of splenocyte viability by 
trypan blue exclusion after 24-h culture of B6 and Chr splenocytes with 
Ly294002 or DMSO control (n = 3). *, P = 0.0326 compared with B6 DMSO; 
#, P = 0.006 compared with B6 DMSO. All error bars represent means ± SD.JEM VOL. 203, October 30, 2006  2537 
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in the context of the reduced (but not completely ablated) 
nuclear levels of ICSBP observed in 12/15-LO–defi  cient 
  animals. Both models also display an initial MPD that transi-
tions to a transplantable leukemia in a subset of animals over 
time. Additionally, it is important to note that both ICSBP 
and 12/15-LO are involved in infl  ammation (43–46), which 
may mediate in part their eff  ects on leukemic disease, as many 
contemporary studies indicate that there may be a stronger 
connection between infl  ammation and carcinogenesis than 
previously recognized (47). Finally, mouse ICSBP and 12/15-
LO share a high degree of homology with their human coun-
terparts (48, 49), each are down-regulated in cells from CML 
patients (16, 21), and both can suppress human CML growth; 
therefore, both of these molecules are mechanistically rele-
vant to human pathology. The lack of requirement for Abl 
activation in the 12/15-LO and ICSBP-defi  cient models is of 
particular interest considering the resistance to Abl inhibitors 
in a substantial proportion of myeloid leukemia patients and 
the role of the PI3-K pathway in many of these cases (9).
PI3-K is activated by cellular stress and various cytokine 
pathways, promoting cell survival, metabolism, and growth (50). 
Mice defi  cient in PTEN, a suppressor of PI3-K–mediated 
Akt activation, succumb to myeloid leukemias (51). Moreover, 
PI3-K inhibitors have been shown to kill imatinib-resistant 
leukemic cells, underscoring the importance of the PI3-K 
pathway in CML. However, because activation of PI3-K 
can be both Abl-dependent and -independent (9, 52), the 
PI3-K–dependent nature of the Alox15 syndrome does not 
readily elucidate whether 12/15-LO may be acting down-
stream of or in parallel to the Abl signaling cascade.
The role of 12/15-LO in regulating PI3-K signaling, es-
pecially in myeloid cells, was previously unknown. However, 
others have shown that the 12/15-LO products 13(S)-HODE 
and 15(S)-HETE up- and down-regulate, respectively, Akt phos-
phorylation in prostate cells (37), whereas 12/15-LO prod-
ucts uniformly up-regulate Akt phosphorylation in vascular 
smooth muscle cells (53). Thus, a cell-type selective eff  ect of 
12/15-LO on PI3-K signaling is apparent and will be of great 
interest to study in myeloid cells.
We have demonstrated decreased nuclear accumulation 
of ICSBP in Alox15 myeloid cells, which may be the result 
of PI3-K–mediated aberrant phosphorylation of ICSBP. In 
agreement with our study, it has been reported that tyrosine 
phosphorylation of ICSBP can decrease its direct binding to 
DNA, thereby limiting its ability to repress gene transcription 
(36). However, this phosphorylation also increases its binding 
to other transcription factors (36), enabling ICSBP to induce 
gene expression. Indeed, others have shown that phosphory-
lation of ICSBP on tyrosines 92 and 95 promotes its positive 
regulation of neurofi  bromin 1 expression without aff  ecting 
ICSBP suppressor function, thereby promoting myeloid cell 
diff  erentiation in vitro (54, 55). On the other hand, our data 
suggest that increased tyrosine phosphorylation of ICSBP can 
also promote MPD, likely through acting on distinct tyro-
sines. Thus, it will be important in future studies to charac-
terize which tyrosine residues are phosphorylated as a result 
of 12/15-LO–mediated PI3-K pathway activity. In either 
case, the increased phosphorylation of ICSBP in our model 
may either subject it to a more rapid nuclear turnover 
  secondary to decreased DNA binding or directly suppress its 
nuclear translocation. Our working model of the 12/15-LO–
dependent regulation of ICSBP is presented in Fig. 10.
In addition to mouse MPD, several observations signify 
a potentially important role for 12/15-LO in human CML. 
12/15-LO is expressed in human hematopoietic tissues and 
myeloid cells, its products are both diminished in and can 
suppress human myeloid leukemia (21), and the Alox15 locus 
maps to a region of chromosome 17p13 implicated in human 
myeloid leukemogenesis (23). Though a few other candidate 
genes are being considered on chromosome 17, our study 
represents the fi  rst direct evidence of the involvement of a par-
ticular locus in this susceptibility region in myeloid leukemia. 
Thus, it is of great interest to determine whether, as our data 
and that of others suggest, the Alox15 gene is mutated in 
  human myeloid leukemias. We are currently investigating 
this possibility.
Further dissecting the mechanism by which 12/15-LO 
suppresses MPD will uncover novel regulatory pathways in 
hematopoiesis and may pave the way for the development of 
additional targeted therapies for the treatment of myeloid 
leukemias and other cancers.
MATERIALS AND METHODS
Mice, cells, and reagents. C57BL/6 and Alox15 mice on a C57BL/6 
background (backcrossed 11 generations) were purchased from The Jackson 
Laboratory and housed and bred in the Wistar Institute Animal Facility. 
  Severe combined immunodefi  ciency mice were purchased from the Wistar 
Institute Animal Facility. All animals were treated in accordance with a   Wistar 
Institute protocol approved by the institutional animal care and use committee. 
K562 cells were purchased from the American Type Culture Collection. 
Ly294002 and PD146176 were purchased from Calbiochem and Sigma-
  Aldrich, respectively. STI571 was supplied by Novartis. K562 cells were 
  nucleofected (Amaxa) according to the manufacturer’s optimized protocol.
Figure 10.  Potential mechanisms by which 12/15-LO may   regulate 
ICSBP. Absence of 12/15-LO leads to increased PI3-K pathway activation, 
possibly via loss of inhibition of activators such as PDK1 or gain of activity of 
PTEN. PI3-K–dependent phosphorylation of ICSBP may reduce nuclear levels 
by diminished nuclear translocation, increased   nuclear turnover, or both.2538  12/15-LO SUPPRESSES MYELOPROLIFERATIVE DISEASE | Middleton et al.
Lipid quantifi  cation. Unperfused fresh spleens were cut into sections in 
duplicate and stimulated for 20 min with 1 μM ionomycin and 200 nM PMA 
in serum-free media. Some of the supernatant was used for lipoxin A4 analysis 
by ELISA (Oxford Biomedical Research, Inc.). The rest of the supernatant 
was extracted for analysis by stable isotope dilution normal phase chiral liquid 
chromatography (LC) coupled with electron capture atmospheric pressure 
chemical ionization (APCI)/mass spectrometry (MS) as described previously 
(49). In brief, samples were spiked with deuterium-labeled internal standards, 
adjusted to pH 3 with 2.5 N hydrochloric acid, and extracted with 2 × 4 ml 
diethyl ether. The organic layer was evaporated to dryness under nitrogen, 
derivatized with 2,3,4,5,6-pentafl  uorobenzyl bromide in the presence of 
  diisopropylethylamine, and evaporated to dryness under a stream of nitrogen. 
Derivatized samples were reconstituted in 100 μl of hexane/ethanol (97:3, 
vol/vol) and 20 μl was analyzed by LC/electron capture APCI/MS system 
for analysis. Quantitation was performed by comparison of peak area ratios of 
the analytes to their relevant stable isotope internal standard and interpolation 
of area ratios from a standard curve (49).
Transfer experiments. 8–10-wk-old wild-type mice were injected via the 
tail vein with 0.5 × 106 (Alox15 crisis) or 107 (Alox15 chronic and C57BL/6) 
splenocytes or 2 × 106 bone marrow cells, monitored every other day, and 
killed at 6 or 10 wk after transfer. Tumor transfer was assessed by blinded mor-
phological characterization of the spleens by hematoxylin and eosin (H&E). 
The presence of Alox15 donor cells in the transplanted mice was confi  rmed by 
PCR of the spleen DNA with primers specifi  c for the neomycin cassette in-
troduced by the Alox15 targeting construct (see Primer sequences).
Histology. Blood samples were collected from the inferior vena cava, anti-
coagulated with EDTA, and kept on ice before slide preparation. Bone mar-
row cells were collected by fl  ushing the femurs of wild-type and Alox15 
mice. Cytospin slides were stained using Kwik-Diff   reagents for Wright 
stains (Thermo Electron). Tissue samples were frozen in Tissue-Tek OCT 
and stored at −80°C. Morphology was analyzed in 8-μm sections stained 
with Gill’s H&E. Tdt-mediated dUTP-biotin nick-end labeling staining for 
apoptotic cells was performed on three sections of spleen per mouse using 
a staining kit (Roche Applied Science) according to the manufacturer’s 
  instructions. The number of positive cells was quantifi  ed using Image-Pro 
software (Media Cybernetics).
Flow cytometry. Single cell suspensions of splenocytes, bone marrow cells, 
and Histopaque 1083–purifi   ed (Sigma-Aldrich) peripheral mononuclear 
cells were prepared and depleted of red blood cells by lysis in ammonium 
chloride buff  er, and cells were stained using 2 μg/ml directly labeled specifi  c 
antibody or isotype-matched antibodies as controls. Compensation was per-
formed using anti-CD4 or Mac-1 (FITC) and anti-CD8 or Mac-1 (PE) 
staining. All fl  ow cytometric antibodies were purchased from BD Biosci-
ences. Cells were washed and analyzed using a BD FACSCalibur machine 
(BD Biosciences). For sorting, cells were stained as described earlier in this 
paragraph and sorted for the populations indicated in the fi  gures at the   Wistar 
Institute Flow Cytometry Core facility.
Propidium iodide staining. Single cell suspensions were fi  xed in ice-cold 
70% ethanol at 4C° for 1 h, washed with PBS, and resuspended in 50 μg/ml 
propidium iodide containing 1.5 mM sodium citrate and 5 μg/ml RNase 
A in PBS. Samples were analyzed by fl  ow cytometry.
Lysates, immunoprecipitation, and Western blots. RBC-depleted 
splenocytes were prepared as in Flow cytometry, and nuclear lysates were 
prepared using the NucBuster kit (EMD Biosciences) according to the man-
ufacturer’s instructions. For cytoplasmic lysates, extracts were prepared from 
isolated cells using 1% NP-40 lysis buff  er with phosphatase and protease 
  inhibitors, whereas total extracts were prepared using M-PER (Bio-Rad 
Laboratories) according to manufacturer’s instructions. For immunoprecipi-
tation, extracts were normalized to total protein concentration using a Bradford 
assay (Bio-Rad Laboratories), according to manufacturer’s instructions, and 
immunoprecipitated overnight with 1 μg of antibody, captured with protein 
G beads, and washed fi  ve times with 0.1% SDS buff  er before electrophoresis. 
For Western analysis of unprecipitated extracts, samples were normalized to 
total protein using Bradford assay according to manufacturer’s instructions, 
resolved by 10% SDS page gel electrophoresis, transferred to polyvinylidene 
difl  uoride membranes, and immunoblotted with specifi  c antibodies, as de-
scribed in Results. All immunoblotting antibodies were obtained from Santa 
Cruz Biotechnology, Inc., except the anti-Crk antibody, which was pur-
chased from BD Biosciences, and anti-phosphoAkt (Ser473), which was 
purchased from Cell Signaling.
Reverse transcription reaction/quantitative real-time PCR. Total 
RNA was extracted from splenocytes using TRIzol (Invitrogen) according 
to manufacturer’s instructions. RNA was treated with Turbo DNase 
  (Ambion) according to the manufacturer’s instructions to remove any con-
taminating genomic DNA, and the absence of appreciable genomic DNA 
was confi  rmed by real-time PCR of the treated RNA. RNA was normal-
ized by OD, and reverse transcription reaction was performed using a cDNA 
synthesis kit (Applied Biosystems) according to the manufacturer’s instruc-
tions. Quantitative real-time PCR analysis was performed using Sybr green 
Master Mix (Applied Biosystems) and analyzed using the ABI 7000 machine 
(Applied Biosystems). Gene-specifi  c primers (see the next paragraph) were 
designed using Primer Express (Applied Biosystems), and gene expression 
levels were normalized using β-actin as an internal control.
Primer sequences. The following primer sequences were used: 
β-  actin, (forward) 5′−T  C  A  G  C  A  A  G  C  A  G  G  A  G  T  A  C  G  A  T  G  -3′ and (reverse) 
5′−A  A  C  A  G  T  C  C  G  C  C  T  A  G  A  A  G  C  A  C  T  T  -3′; ICSBP (forward) 5′-T  G  G  G-
C  A  G  T  T  T  T  T  A  A  A  G  G  G  A  A  G  T  T  -3′ and (reverse) 5′-A  C  A  G  C  G  T  A  A  C  C  T-
C  G  T  C  T  T  C  C  A  -3′; 12/15-LO (forward) 5′-A  C  C  C  C  A  C  C  G  C  C  G  A  T  T  T  T   
and (reverse) 5′-A  G  C  T  T  C  G  G  A  C  C  C  A  G  C  A  T  T  T  ; and neomycin cas-
sette (forward) 5′-T  T  G  G  G  T  G  G  A  G  A  G  G  C  T  A  T  T  C  G  -3′ and (reverse) 
5′-A  A  C  A  C  G  G  C  G  G  C  A  T  C  A  G  A  -3′.
Statistical analysis. One-way analysis of variance (for comparing more 
than two groups) and t-tests (for comparing two groups) were calculated us-
ing Prism software (GraphPad) according to the program’s designation of the 
most statistically valid test for each experiment. The α level was set at 0.05 
for all tests; p-values below this were considered statistically signifi  cant. All 
error bars represent means ± SD.
Online supplemental material. Fig. S1 shows comparable hematopoi-
etic compartments to wild-type controls in young Alox15 mice. Fig. S2 
depicts increased megakaryocytes and decreased red blood cell numbers in 
Alox15 mice. Fig. S3 shows myeloid infi  ltrates in the skin of moribund 
Alox15 mice. Online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20061444/DC1.
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